Integrated Analysis of Bulk and Single-cell RNA Sequencing Reveals the Impact of Nicotinamide and Tryptophan Metabolism on Glioma Prognosis and Immunotherapy Sensitivity

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2024 Oct 29

PMID 39468708

Authors

Sen Wang

Shen Gao

Shaochong Lin

Xiaofeng Fang

Haopeng Zhang

Man Qiu

Kai Zheng

Yupeng Ji

Baijun Xiao

Xiangtong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Nicotinamide and tryptophan metabolism play important roles in regulating tumor synthesis metabolism and signal transduction functions. However, their comprehensive impact on the prognosis and the tumor immune microenvironment of glioma is still unclear. The purpose of this study was to investigate the association of nicotinamide and tryptophan metabolism with prognosis and immune status of gliomas and to develop relevant models for predicting prognosis and sensitivity to immunotherapy in gliomas.

Methods: Bulk and single-cell transcriptome data from TCGA, CGGA and GSE159416 were obtained for this study. Gliomas were classified based on nicotinamide and tryptophan metabolism, and PPI network associated with differentially expressed genes was established. The core genes were identified and the risk model was established by machine learning techniques, including univariate Cox regression and LASSO regression. Then the risk model was validated with data from the CGGA. Finally, the effects of genes in the risk model on the biological behavior of gliomas were verified by in vitro experiments.

Results: The high nicotinamide and tryptophan metabolism is associated with poor prognosis and high levels of immune cell infiltration in glioma. Seven of the core genes related to nicotinamide and tryptophan metabolism were used to construct a risk model, and the model has good predictive ability for prognosis, immune microenvironment, and response to immune checkpoint therapy of glioma. We also confirmed that high expression of TGFBI can lead to an increased level of migration, invasion, and EMT of glioma cells, and the aforementioned effect of TGFBI can be reduced by FAK inhibitor PF-573,228.

Conclusions: Our study evaluated the effects of nicotinamide and tryptophan metabolism on the prognosis and tumor immune microenvironment of glioma, which can help predict the prognosis and sensitivity to immunotherapy of glioma.

References

Morad G, Helmink B, Sharma P, Wargo J . Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184(21):5309-5337. PMC: 8767569. DOI: 10.1016/j.cell.2021.09.020. View

Liu S, Galat V, Galat Y, Lee Y, Wainwright D, Wu J . NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021; 14(1):7. PMC: 7788999. DOI: 10.1186/s13045-020-01014-w. View

Puthdee N, Sriswasdi S, Pisitkun T, Ratanasirintrawoot S, Israsena N, Tangkijvanich P . The LIN28B/TGF-β/TGFBI feedback loop promotes cell migration and tumour initiation potential in cholangiocarcinoma. Cancer Gene Ther. 2021; 29(5):445-455. PMC: 9113936. DOI: 10.1038/s41417-021-00387-5. View

Jung M, Lee K, Im Y, Seok S, Chung H, Kim D . Nicotinamide (niacin) supplement increases lipid metabolism and ROS-induced energy disruption in triple-negative breast cancer: potential for drug repositioning as an anti-tumor agent. Mol Oncol. 2022; 16(9):1795-1815. PMC: 9067146. DOI: 10.1002/1878-0261.13209. View

Sulzmaier F, Jean C, Schlaepfer D . FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014; 14(9):598-610. PMC: 4365862. DOI: 10.1038/nrc3792. View

Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G . Tumor Purity as an Underlying Key Factor in Glioma. Clin Cancer Res. 2017; 23(20):6279-6291. DOI: 10.1158/1078-0432.CCR-16-2598. View

Simonds E, Lu E, Badillo O, Karimi S, Liu E, Tamaki W . Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J Immunother Cancer. 2021; 9(6). PMC: 8183210. DOI: 10.1136/jitc-2020-002181. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Ladomersky E, Zhai L, Lenzen A, Lauing K, Qian J, Scholtens D . IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018; 24(11):2559-2573. PMC: 5984675. DOI: 10.1158/1078-0432.CCR-17-3573. View

10.

Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2024; 1(3):e36. PMC: 10989974. DOI: 10.1002/imt2.36. View

11.

Zhai L, Bell A, Ladomersky E, Lauing K, Bollu L, Nguyen B . Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021; 27(23):6514-6528. PMC: 8639612. DOI: 10.1158/1078-0432.CCR-21-1392. View

12.

Chen A, Martin A, Choy B, Fernandez-Penas P, Dalziell R, McKenzie C . A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015; 373(17):1618-26. DOI: 10.1056/NEJMoa1506197. View

13.

Boutilier A, Elsawa S . Macrophage Polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021; 22(13). PMC: 8268869. DOI: 10.3390/ijms22136995. View

14.

Myers J, Miller J . Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2020; 18(2):85-100. PMC: 8316981. DOI: 10.1038/s41571-020-0426-7. View

15.

Law A, Valdes-Mora F, Gallego-Ortega D . Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. Cells. 2020; 9(3). PMC: 7140518. DOI: 10.3390/cells9030561. View

16.

Navarro M, Gomez de Las Heras M, Mittelbrunn M . Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing. Br J Pharmacol. 2021; 179(9):1839-1856. PMC: 9292562. DOI: 10.1111/bph.15477. View

17.

Ahmed A, Mills A, Ibrahim A, Temple J, Blenkiron C, Vias M . The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007; 12(6):514-27. PMC: 2148463. DOI: 10.1016/j.ccr.2007.11.014. View

18.

Fico F, Santamaria-Martinez A . TGFBI modulates tumour hypoxia and promotes breast cancer metastasis. Mol Oncol. 2020; 14(12):3198-3210. PMC: 7718944. DOI: 10.1002/1878-0261.12828. View

19.

Chu J, Gao F, Yan M, Zhao S, Yan Z, Shi B . Natural killer cells: a promising immunotherapy for cancer. J Transl Med. 2022; 20(1):240. PMC: 9125849. DOI: 10.1186/s12967-022-03437-0. View

20.

Ma B, Ueda H, Okamoto K, Bando M, Fujimoto S, Okada Y . TIMP1 promotes cell proliferation and invasion capability of right-sided colon cancers via the FAK/Akt signaling pathway. Cancer Sci. 2022; 113(12):4244-4257. PMC: 9746056. DOI: 10.1111/cas.15567. View